AUROPHARMA
725.85
2019-01-04
AUROBINDO PHARMA LTD.
Profitability metrics STANDALONE CONSOLIDATED
Asset Turnover 0.6347 0.7662
Current ratio 3.9 2.6
WC days 252.32 175.7
EBITDA (%) 26.79 23.55
FCF (Rs Cr.) 372 892
ROCE (%) 17.49 20.18
ROE (%) 18.16 20.74

Solvency metrics STANDALONE CONSOLIDATED
Cash Ratio 0.1 0.25
Div. payout (%) 12.12 9.07
Int. Coverage 45.21 42.55
LT D/E 0.37 0.41
Solvency Ratio 0.58 0.62

Valuation STANDALONE CONSOLIDATED
Beta 0.7326 0.7326
Div. yield (%) 1 1
EV (Rs Cr.) 36122.4 36157.7
P/BV 3.27 2.8
P/E 18.01 13.47
PEG 3 2.69
P/S 3.18 1.98

Balance sheet metrics STANDALONE CONSOLIDATED
BV/share 170.39 199.37
3Y growth BV/s (%) -7 13
Cash (Rs Cr.) 245.9 1261.62
Total Debt (Rs Cr.) 3719 4770
Net block (Rs Cr.) 3393 6521

P&L metrics STANDALONE CONSOLIDATED
DPS 3.75 3.75
EPS 30.94 41.36
Net Income (Rs Cr.) 1813 2423
Operating profit (Rs Cr.) 2670 3772
No. of o/s shares 58.59 58.59
Revenue (Rs Cr.) 10270 16463
Total Income (Rs Cr.) 10351 16568

Cash Flow metrics STANDALONE CONSOLIDATED
CEPS (%) 1560 3337
3Y growth CEPS -0.23 -0.21
CFF (Rs Cr.) 440 864
CFI (Rs Cr.) -981 -1927
CFO (Rs Cr.) 914 1955
FCF (Rs Cr.) 372 892
3Y growth Op. CF (%) 55 58

Growth metrics STANDALONE CONSOLIDATED
3Y growth dividends (%) -100 -100
1Q growth EBITDA (%) 0 0
3Y growth EBITDA (%) 19 45
4Q growth EBITDA (%) 0 0
1Q growth EPS (%) 0 0
3Y growth EPS (%) -40 -23
4Q growth EPS (%) 0 0
3Y growth Net inc. (%) 20 54
1Y growth Op. CF (%) -63 -40
1Q growth revenue (%) 0 0
3Y growth revenue (%) 27 36
4Q growth revenue (%) 0 0